Bergmann Carsten, Senderek Jan, Schneider Frank, Dornia Christian, Küpper Fabian, Eggermann Thomas, Rudnik-Schöneborn Sabine, Kirfel Jutta, Moser Markus, Büttner Reinhard, Zerres Klaus
Department of Human Genetics, Aachen University, Aachen, Germany.
Hum Mutat. 2004 May;23(5):487-95. doi: 10.1002/humu.20019.
Autosomal recessive polycystic kidney disease (ARPKD) is one of the most common hereditary renal cystic diseases in children. The clinical spectrum ranges from stillbirth and neonatal demise to survival into adulthood. In a given family, however, patients usually display comparable phenotypes. Many families who lost a child with severe ARPKD desire an early and reliable prenatal diagnosis (PD). Given the limitations of antenatal ultrasound, this is only feasible by molecular genetics that became possible in 1994 when PKHD1, the locus for ARPKD, was mapped to chromosome 6p. However, linkage analysis might prove difficult or even impossible in families with diagnostic doubts or in whom no DNA of an affected child is available. In such cases the recent identification of the PKHD1 gene provides the basis for direct mutation testing. However, due to the large size of the gene, lack of knowledge of the encoded protein's functional properties, and the complicated pattern of splicing, significant challenges are posed by PKHD1 mutation analysis. Thus, it is important to delineate the mutational spectrum and the reachable mutation detection rate among the cohort of severely affected ARPKD patients. In the present study, we performed PKHD1 mutation screening by DHPLC in a series of 40 apparently unrelated families with at least one peri- or neonatally deceased child. We observed 68 out of an expected 80 mutations, corresponding to a detection rate of 85%. Among the mutations identified, 23 were not reported previously. We disclosed two underlying mutations in 29 families and one in 10 cases. Thus, in all but one family (98 percent;), we were able to identify at least one mutation substantiating the diagnosis of ARPKD. Approximately two-thirds of the changes were predicted to truncate the protein. Missense mutations detected were nonconservative, with all but one of the affected amino acid residues found to be conserved in the murine ortholog. PKHD1 mutation analysis has proven to be an efficient and effective means to establish the diagnosis of ARPKD.
常染色体隐性多囊肾病(ARPKD)是儿童中最常见的遗传性肾囊性疾病之一。其临床症状范围从死产和新生儿死亡到存活至成年。然而,在特定家族中,患者通常表现出相似的表型。许多失去患有严重ARPKD孩子的家庭渴望进行早期且可靠的产前诊断(PD)。鉴于产前超声的局限性,只有通过分子遗传学方法才可行,这在1994年成为可能,当时ARPKD的致病基因位点PKHD1被定位到6号染色体短臂。然而,在存在诊断疑问的家族中或无法获得患病儿童DNA的家族中,连锁分析可能会很困难甚至无法进行。在这种情况下,最近PKHD1基因的鉴定为直接突变检测提供了基础。然而,由于该基因规模庞大、对编码蛋白质功能特性缺乏了解以及剪接模式复杂,PKHD1突变分析面临重大挑战。因此,明确严重受累的ARPKD患者群体中的突变谱和可达到的突变检测率很重要。在本研究中,我们通过变性高效液相色谱(DHPLC)对一系列40个明显无亲缘关系的家族进行了PKHD1突变筛查,这些家族中至少有一个围产期或新生儿期死亡的孩子。我们在预期的80个突变中观察到68个,检测率为85%。在鉴定出的突变中,有23个此前未被报道。我们在29个家族中发现了两个潜在突变,在10个病例中发现了一个。因此,除了一个家族外(98%),我们能够在所有家族中鉴定出至少一个证实ARPKD诊断的突变。大约三分之二的变化预计会导致蛋白质截短。检测到的错义突变是非保守的,除一个受影响的氨基酸残基外,其余所有残基在小鼠直系同源物中均保守。PKHD1突变分析已被证明是确立ARPKD诊断的一种有效手段。